Saccharomyces boulardii combined with triple therapy alter the microbiota in the eradication of Helicobacter pylori infection.

2024-06-07
Scientific reports 14(1)
- Yan Zhang
- Bingyun Lu
- Yu Dong
- Yifeng Zhang
- Qianming Du
- Ye Chen
- Zhenyu Zhang

PubMed: 38849408
DOI: 10.1038/s41598-024-63894-z

Study Design

Type: Randomized Controlled Trial (RCT)
Sample size: n = 144
Population: 144 patients who tested positive for H. pylori and diagnosed with non-ulcer dyspepsia
Methods: Patients were categorized into three groups using a subsection randomization method and received initial H. pylori eradication treatments
Duration: 44 days

Large Human Trial
Rigorous Journal

To assess the effectiveness and safety of combining Saccharomyces boulardii powder with triple therapy as a primary approach for eradicating H. pylori infection, a total of 144 patients who tested positive for H. pylori and diagnosed with non-ulcer dyspepsia underwent endoscopy at two national centers between June 2017 and March 2019 were included. The patients were categorized into three groups using a subsection randomization method and received initial H. pylori eradication treatments. Microbial composition, eradication rates, symptom alleviation, and adverse reactions were monitored on the 14th and 44th days post-treatment. According to PP analysis showed the eradication rates for the SRAC group was 75%, BRAC was 93.18% and RAC was 65.2%. Group BRAC exhibited a marginally higher eradication rate compared to other groups. However, patients receiving Saccharomyces boulardii treatment exhibited an overall reduction in initial dyspepsia symptoms by the end of the treatment period. When employed as a primary strategy, the combination of Saccharomyces boulardii powder with triple therapy displayed notable efficacy and smaller gastrointestinal side effects in eradicating initial H. pylori infections among non-ulcer dyspepsia patients. Moreover, this approach demonstrated advantages in alleviating symptoms, exhibited favorable tolerance, and maintained a high level of clinical safety.

Research Insights

saccharomyces boulardii→Increased Helicobacter pylori Eradication Rate
According to PP analysis showed the eradication rates for the SRAC group was 75%, BRAC was 93.18% and RAC was 65.2%. Group BRAC exhibited a marginally higher eradication rate compared to other groups.
Effect
Beneficial
Effect size
Moderate
saccharomyces boulardii→Reduced Abdominal Pain
patients receiving Saccharomyces boulardii treatment exhibited an overall reduction in initial dyspepsia symptoms by the end of the treatment period.
Effect
Beneficial
Effect size
Small

Adverse Events Reported

saccharomyces boulardii→Overall tolerability
this approach demonstrated advantages in alleviating symptoms, exhibited favorable tolerance, and maintained a high level of clinical safety.
Finding
Reported
saccharomyces boulardii→adverse reactions
Microbial composition, eradication rates, symptom alleviation, and adverse reactions were monitored on the 14th and 44th days post-treatment.
Finding
Reported
saccharomyces boulardii→gastrointestinal side effects
the combination of Saccharomyces boulardii powder with triple therapy displayed notable efficacy and smaller gastrointestinal side effects in eradicating initial H. pylori infections among non-ulcer dyspepsia patients.
Finding
Reported